✦ LIBER ✦

1047: Castleman Disease with Paraneoplastic Pemphigus: Ultrasound Finding

✍ Scribed by Luzeng Chen; Bin Wang; Yan Xiong; Ting Li

Book ID: 108295796
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 102 KB
Volume: 35
Category: Article
ISSN: 0301-5629
DOI: 10.1016/j.ultrasmedbio.2009.06.429

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paraneoplastic pemphigus in association

Paraneoplastic pemphigus in association with Castleman's disease

✍ O.V. Nikolskaia; C.H. Nousari; G.J. Anhalt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Paraneoplastic pemphigus with Castleman'

Paraneoplastic pemphigus with Castleman's disease and bronchiolitis obliterans

✍ Tarun Jindal; Monika Meena; Arvind Kumar; Binod K. Khaitan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Successful Immunomodulatory Therapy in C

Successful Immunomodulatory Therapy in Castleman Disease with Paraneoplastic Pemphigus Vulgaris

✍ Zsofia Miltenyi; Judit Toth; Andrea Gonda; Ildiko Tar; Eva Remenyik; Arpad Illes 📂 Article 📅 2008 🏛 Springer Netherlands 🌐 English ⚖ 423 KB

Paraneoplastic pemphigus in association

Paraneoplastic pemphigus in association with Castleman disease of the pararenal retroperitoneum

✍ Xiang WEN; Xian JIANG 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 254 KB

Paraneoplastic pemphigus associated with

Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease

✍ A.V. Marzano; P. Vezzoli; F. Mariotti; V. Boneschi; R. Caputo; E. Berti 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

P155 Paraneoplastic pemphigus vulgaris w

P155 Paraneoplastic pemphigus vulgaris with Castleman disease and successful immunomodulatory therapy

✍ Zs. Miltenyi; A. Gonda; I. Tar; É. Remenyik; Á. Illés 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

have transfusion necessity, after the 3 month interval from the beginning of the therapy; in 14% of patients Erythropoietin was used to correct the anemic syndrome. The dosage was 10000 IU 3 times per week subcutaneous. Since no severe granulocytopenia cases were reported the administration of GM-CS